Evaluating the cost containment potential of clinical guidelines.
New expensive biotechnology products create financial as well as clinical dilemmas for hospitals. Clinical guidelines that govern the use of these new products are often viewed as the best response to these dilemmas. This article describes a prospective analysis of the impact of one new drug and the guidelines developed to control its use. A simple model of clinical decision making is used to evaluate alternative scenarios. The analysis illustrates the importance of evaluating the cost containment potential of clinical guidelines before they are implemented.
Widener University, Chester, Pennsylvania 19013.
C E
CE
Carpenter
D B
DB
Nash
N E
NE
Johnson
D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use; D003363:Cost Control; D003661:Decision Support Techniques; D004731:Endotoxins / Q000276:immunology; D016905:Gram-Negative Bacterial Infections / Q000191:economics* / Q000401:mortality / Q000628:therapy; D006801:Humans; D017410:Practice Guidelines as Topic
D000911:Antibodies, Monoclonal; D004731:Endotoxins